Navigation Links
Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women

Benefits of Arimidex (anastrozole) over tamoxifen at preventing all forms of breast cancer recurrence increase over time - even four years after

treatment ends

SAN ANTONIO, Dec. 14 /PRNewswire/ -- New data from ATAC*, one of the world's largest and longest-running studies in postmenopausal women with early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. For the first time, anastrozole has been shown to be the only treatment of its type to be increasingly better than tamoxifen in preventing tumours from returning.(1),(2) If cancer returns, women are much more likely to die - therefore, preventing breast cancer from returning ("recurrence") is key to saving lives.

To view the Multimedia News Release, go to:

The landmark results - presented today at the prestigious annual San Antonio Breast Cancer Symposium (SABCS), USA and also published online in The Lancet Oncology - show that even four years after a woman's treatment ends, the protective effect of anastrozole in reducing the risk of hormone-sensitive early breast cancer from returning continues to increase. Overall, women in the ATAC trial taking anastrozole were 24% less likely to have their cancer come back, compared with those taking tamoxifen.(1),(2) This demonstrates the long-term impact of treatment decisions made at diagnosis and confirms the importance of starting treatment with anastrozole to help more women beat this devastating disease. Breast cancer currently affects 1.1 million women worldwide per year 3 and hormone-sensitive early disease accounts for around 75% of all cases of breast cancer in postmenopausal women.(4)

Presenting the data at SABCS, Professor John Forbes, Newcastle Mater Misericordiae Hospital, Australia commented: "Preventing recurrence is the primary goal in breast cancer management. If we can stop the cancer from returning, we can save more lives, more often. These exciting long-term follow-up data show that anastrozole is a more effective treatment option than tamoxifen for postmenopausal women with hormone-sensitive early stage disease - thus it is imperative these women get the most effective treatment at the earliest opportunity after diagnosis."

Professor Forbes continued: "Prior to the ATAC trial, tamoxifen was the standard of care for women with hormone-sensitive disease, with substantial evidence to support its crucial place in practice. However, these new 100- month data from ATAC show us that compared with tamoxifen, anastrozole can significantly reduce the risk of recurrence and minimise life-threatening side effects. Most encouragingly, the data also show us that the protective effect of anastrozole lasts well beyond the standard treatment period of five years and in my opinion confirms there is no longer any rationale for prescribing tamoxifen."

A recent global survey showed that over 70% of physicians believe that telling a patient her breast cancer has come back is worse than giving a diagnosis of early breast cancer.(6) Recurrence, in the same breast, in the opposite breast or at a distant tumour site means that the cancer is more likely to be incurable and the patient is at risk of a bad outcome. It is therefore essential for both patients and their physicians** to know they are on a better therapy than tamoxifen to prevent the disease returning.

The impact of treatment on quality of life is also an important consideration in early breast cancer, and data have shown that the clinical benefits of anastrozole are achieved without adversely affecting the quality of patients' lives.(5)

"The ATAC 100-month data confirm that anastrozole is now the gold standard treatment for post-menopausal women with hormone-sensitive early breast cancer, irrespective of their recurrence risk, and is set to improve the outcomes of patients worldwide," commented Professor Anthony Howell, Christie Hospital, UK.

ATAC 100-month results summary:

-- After a median follow-up of over 8 years (100 months), compared with

tamoxifen, anastrozole significantly:(1),(2)

-- reduces the risk of all recurrences by 24% (HR 0.76 [0.67-0.87];


-- improves disease free survival by 15% (HR 0.85 [0.76-0.94]; p=0.003)

-- reduces the risk of distant metastases (recurrence elsewhere in the

body) by 16% (HR 0.84 [0.72-0.97]; p=0.022)

-- reduces the incidence of contralateral breast cancer (cancer in the

opposite breast) by 40% (OR 0.60 [0.42-0.85]; p=0.004)

-- Prescribing anastrozole from the start means fewer patients have to

be told the devastating news that their breast cancer has


Notes to Editors

For more information, to view a presentation of the ATAC 100 data by Professor John Forbes or to download the ATAC 100 publication in The Lancet Oncology, please visit

The study will be published early online (00.01 GMT Saturday 15 December) and in the January edition of The Lancet Oncology.

* ATAC: Arimidex, Tamoxifen, Alone or in Combination

** Physicians: medical oncologists, gynaecologists and breast cancer


Patients: postmenopausal women diagnosed with early breast cancer in

the past five years and who had undergone breast cancer surgery

Broadcast-quality video

For broadcast-standard video supporting this press release, please visit If you are a first-time user, please take a moment to register. In case you have any questions, please email

'More Positive Conversations' global survey

The 'More Positive Conversations' survey was conducted online and via telephone interviews by Harris Interactive on behalf of AstraZeneca. The survey involved 1,062 physicians and patients from France, Germany, Italy, the United Kingdom and the US.


AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

Arimidex (anastrozole) is a trademark, the property of the AstraZeneca group of companies.


1. The ATAC Trialist Group -Effect of anastrozole and tamoxifen as

adjuvant treatment for early-stage breast cancer; 100 month analysis of

the ATAC trial -published online, Lancet Oncology Saturday 15 December

2. Forbes J, on behalf on the ATAC Trialist's Group. ATAC: 100 month

median follow-up shows continued superior efficacy and no excess

fracture risk for anastrozole compared with tamoxifen after treatment

completion. Abstract no 41. San Antonio Breast Cancer Symposium 2007.

3. Parkin, D.M., E. Laara, and C.S. Muir, Estimates of the worldwide

frequency of sixteen major cancers in 1980. Int J Cancer, 1988. 41(2):

p. 184-97.

4. What role to hormones play in breast cancer

treatment. Available from

(Last accessed October 2007)

5. Cella et al, Quality of life of postmenopausal women in the ATAC

('Arimidex', Tamoxifen, Alone or in Combination) trial after completion

of 5 years' Adjuvant Treatment for early breast cancer. Breast Cancer

Research and Treatment, 2006. 100(3): p. 273-284.

6. Data on file, 'More Positive Conversations' global survey, conducted by

Harris Interactive (US) March-May 2007.

"The greatest fear for women who have been treated for early breast cancer is to have their cancer return, which ultimately means their disease is incurable. However, these new data show that with anastrozole, women have the best possible chance yet to live cancer-free - even after their treatment has finished." Professor Lesley Fallowfield, Director, Cancer Research UK Psychosocial Oncology Group, University of Sussex, UK

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Tapestry Reports Second Quarter 2007 Results
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:11/29/2015)... Nov. 29, 2015   National Decision Support Company ... client base, including notable statewide implementations. As a ... solution, ACR Select, more than 1 million times ... workflow. ACR Select provides real-time feedback on the ... and has been implemented at over 100 healthcare ...
(Date:11/27/2015)... November 27, 2015 --> ... to go online. The potential to save costs, improve ... and far from fully exploited as yet. Here, particular ... records, either via mobile tablet or directly at the ... ) -->      (Photo: ...
(Date:11/27/2015)... 27, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), ... biopharmaceuticals company UCB S.A. (Euronext: UCB). ... acquired KU from UCB for total consideration of ... a customary working capital adjustment, a deduction of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... conference will begin on Sunday, March 6, 2016, at Caesars Palace in Las ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
Breaking Medicine News(10 mins):